retatrutide triple agonist phase 2 obesity trial Eli Lilly's shows promising weight loss results in 3 Mazdutide vs retatrutide: dual agonist

For individuals with normal or near-normal body weight, GLP-1 medications can address metabolic dysfunction, insulin resistance, and cardiovascular risk factors that standard BMI categories often overlook

Concept of the pathogenesis and treatment of cholelithiasis

China trial scrutiny introduces a political dimension that could reshape deal flow, development timelines, and the global division of clinical labor

References: Anderson K et al (2021): Is metformin effective for reducing weight in obese or overweight adolescents

Tirzepatide Starting at: $495 A once-weekly dual GIP and GLP-1 therapy built around your physiology, sourced through a licensed compounding pharmacy, and overseen by our medical director

How much weight will I lose on a GLP-1